<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald J Wong, BA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vinod K Bhutani, MD, FAAP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nearly all newborn infants develop elevated bilirubin levels (ie, total serum bilirubin [TSB] &gt;1 mg/dL [17 micromol/L], which is the upper limit of normal for adults). As TSB levels increase, the newborn may develop visible jaundice. Neonates with severe hyperbilirubinemia (defined as TSB &gt;25 mg/dL [428 micromol/L] in newborns ≥35 weeks gestation) are at risk for developing bilirubin-induced neurologic disorders (BIND).</p><p>The epidemiology, risk factors, clinical manifestations, and neurologic complications of neonatal unconjugated hyperbilirubinemia are reviewed here. Other related issues are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Pathogenesis and etiology of neonatal hyperbilirubinemia (see  <a class="medical medical_review" href="/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Screening for hyperbilirubinemia in newborns ≥35 weeks gestation (see  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a>) </p><p class="bulletIndent1"><span class="glyph">●</span>Management of neonatal hyperbilirubinemia (see  <a class="medical medical_review" href="/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"</a> and  <a class="medical medical_review" href="/d/html/121592.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Escalation of care"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperbilirubinemia in preterm infants (GA &lt;35 weeks) (see  <a class="medical medical_review" href="/d/html/5037.html" rel="external">"Unconjugated hyperbilirubinemia in preterm infants &lt;35 weeks gestation"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Conjugated (direct) hyperbilirubinemia in neonates (see  <a class="medical medical_review" href="/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>)</p><p></p><p class="headingAnchor" id="H440407233"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign neonatal hyperbilirubinemia</strong> is a transient and normal increase in bilirubin levels occurring in nearly all newborn infants and invariably responds to nutritional support. It has been referred to as "physiologic jaundice."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of hyperbilirubinemia</strong> – Various definitions have been used to define "severe" versus "extreme" or "hazardous" neonatal hyperbilirubinemia. Throughout this topic review, we use the following total serum or plasma bilirubin (TSB) levels to define these terms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe neonatal hyperbilirubinemia </strong>is defined as TSB &gt;25 mg/dL (428 micromol/L). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extreme or hazardous neonatal hyperbilirubinemia</strong> is defined as TSB ≥30 mg/dL (513 micromol/L). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilirubin-induced neurologic disorders (BIND)</strong> refer to the spectrum of neurotoxic injury resulting from selective damage from free (unbound) bilirubin crossing the blood-brain barrier and binding to brain tissue. BIND includes acute and chronic bilirubin encephalopathy (ABE and CBE, respectively), as well as more subtle neurologic dysfunction. The manifestations of BIND, including ABE and CBE, are described below. (See <a class="local">'Consequences of severe hyperbilirubinemia'</a> below.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H4"><span class="h2">Incidence of neonatal hyperbilirubinemia</span><span class="headingEndMark"> — </span>In the neonate, bilirubin values vary substantially from region to region because of differences in breastfeeding practices, racial composition of the population, and the prevalence of genetic factors that affect bilirubin production and metabolism. These factors as well as the use of different definitions to describe the severity of hyperbilirubinemia may contribute to the following observed global variations in the incidence of severe hyperbilirubinemia.</p><p class="bulletIndent1"><span class="glyph">●</span>In studies of newborn infants ≥35 weeks gestation from a large healthcare system in California, the following incidences of hyperbilirubinemia at different total serum bilirubin (TSB) values were reported from birth data collected between 1995 and 1998 [<a href="#rid1">1,2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TSB &gt;20 mg/dL (342 micromol/L) – 2 percent </p><p class="bulletIndent2"><span class="glyph">•</span>TSB &gt;25 mg/dL (428 micromol/L) – 0.14 percent </p><p class="bulletIndent2"><span class="glyph">•</span>TSB &gt;30 mg/dL (513 micromol/L) – 0.01 percent </p><p></p><p class="bulletIndent1">The incidence of TSB &gt;20 mg/dL (342 micromol/L) was lower in infants born to mothers who were self-reported as Black compared with White (0.9 versus 1.5 percent, relative risk [RR] 0.62, 95% CI 0.56-0.69) [<a href="#rid3">3</a>]. However, the risk of developing TSB &gt;30 mg/dL (513 micromol/L) was higher in Black infants (0.13 versus 0.03 percent, RR 4.2, 95% CI 1.33-13.2).</p><p></p><p class="bulletIndent1">In a subsequent birth cohort of infants born between 1995 and 2011 in the same network, the reported incidence of TSB &gt;30 mg/dL (513 micromol/L) was 8.6 per 100,000 live births [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a Danish population-based study from 2000 to 2015, the incidence of TB ≥26.3 mg/dL (450 micromol/L) was 0.042 percent (42 per 100,000 live births) among newborns ≥35 weeks gestation [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective population-based study in the United Kingdom and Ireland between 2003 and 2005, the incidence of TSB &gt;30 mg/dL (513 micromol/L) was 7 per 100,000 live births (0.007 percent) [<a href="#rid6">6</a>]. The mean gestational age (GA) of the 108 identified infants was 38.2 weeks. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective population-based study from Australia performed between 2010 and 2013, the incidence of TSB ≥26.3 mg/dL (450 micromol/L) for newborns greater than 34 weeks GA was 9.4 per 100,000 infants (0.009 percent) [<a href="#rid7">7</a>]. (See <a class="local">'Risk factors'</a> below.)</p><p></p><p class="headingAnchor" id="H56987980"><span class="h2">Trends over time</span><span class="headingEndMark"> — </span>The incidence of severe hyperbilirubinemia (TSB &gt;25 mg/dL [428 micromol/L]) is decreasing, presumably due to early identification and treatment of at-risk newborns  (<a class="graphic graphic_figure graphicRef101082" href="/d/graphic/101082.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a> and  <a class="medical medical_review" href="/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Thresholds for treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a study that compared data from the Canadian Paediatric Surveillance Program with previously published reports, the incidence of TSB ≥24.9 mg/dL (426 micromol/L) in Canada declined from 0.04 to 0.01 percent over a 10-year period from 2002 through 2004 to 2011 through 2013 [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A report from a multicenter health care system in the United States showed a declining rate of infants with TSB levels &gt;25 mg/dL (428 micromol/L) from 2002 to 2010 [<a href="#rid9">9</a>]  (<a class="graphic graphic_figure graphicRef101082" href="/d/graphic/101082.html" rel="external">figure 1</a>). </p><p></p><p class="headingAnchor" id="H6"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H3223391199"><span class="h2">Risk factors for severe hyperbilirubinemia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predischarge bilirubin level</strong> – The strongest predictor of developing progressive to severe hyperbilirubinemia is the newborn's predischarge total serum or plasma bilirubin (TSB) or transcutaneous bilirubin (TcB) level, which is typically measured at 24 to 48 hours after birth [<a href="#rid10">10,11</a>]. The newborn hyperbilirubinemia assessment calculator (<a class="calc calc_professional" href="/d/html/13421.html" rel="external">calculator 1</a>) can be used to assess the risk of developing severe hyperbilirubinemia and determine the hour-specific TSB threshold for treatment. Additional details regarding newborn bilirubin screening and treatment are provided separately. (See  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a> and  <a class="medical medical_review" href="/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"</a>.)</p><p></p><p class="bulletIndent1">Risk assessments are based on total bilirubin rather than unconjugated bilirubin levels alone because neonatal hyperbilirubinemia is mostly due to increased bilirubin production, resulting primarily in unconjugated bilirubin. Cholestasis, which presents with primarily elevated conjugated or direct bilirubin, is a rare cause of neonatal hyperbilirubinemia. (See  <a class="medical medical_review" href="/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical factors associated with increased risk</strong> – In addition to the predischarge bilirubin level, the 2022 guidelines from the American Academy of Pediatrics (AAP) clinical practice guideline recognize the following as key risk factors for developing progressive or severe hyperbilirubinemia [<a href="#rid10">10</a>]  (<a class="graphic graphic_table graphicRef64584" href="/d/graphic/64584.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prematurity – The risk increases with each additional week earlier than 40 weeks of gestation [<a href="#rid11">11-14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early-onset jaundice (within the first 24 hours after birth) [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known or suspected hemolytic disease due to isoimmune-mediated hemolysis from blood group incompatibilities or inherited hemolytic disorders (eg, glucose-6-phosphate dehydrogenase [G6PD] deficiency) [<a href="#rid4">4,7,16</a>]. Hemolysis may be suspected based upon any of the following (see  <a class="medical medical_review" href="/d/html/5933.html" rel="external">"Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management"</a> and  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>ABO or Rh incompatibility (regardless of direct antiglobulin test [DAT] status) </p><p class="bulletIndent3"><span class="glyph">-</span>Early-onset jaundice (within in first 24 hours after birth) </p><p class="bulletIndent3"><span class="glyph">-</span>Rapidly rising TSB levels (&gt;0.3 mg/dL [5 micromol/L] per hour in the first 24 hours; &gt;0.2 mg/dL [3 micromol/L] per hour thereafter)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A parent or sibling who required phototherapy or exchange transfusion as a newborn [<a href="#rid13">13,17</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family history or ancestry suggestive of an inherited hemolytic disorder (eg, G6PD deficiency, hereditary spherocytosis). (See  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cephalohematoma or other significant bruising from birth trauma [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/5031.html" rel="external">"Neonatal birth injuries", section on 'Cephalohematoma'</a> and  <a class="medical medical_review" href="/d/html/5031.html" rel="external">"Neonatal birth injuries"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Down syndrome. (See  <a class="medical medical_review" href="/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Macrosomic (large-for-gestational-age [LGA]) infant of a diabetic mother [<a href="#rid11">11,18,19</a>]. (See  <a class="medical medical_review" href="/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Need for phototherapy during the birth hospitalization.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exclusive breastfeeding with suboptimal intake [<a href="#rid12">12,13,20</a>].</p><p></p><p class="bulletIndent1">For newborns undergoing routine bilirubin screening, these risk factors are used in conjunction with the predischarge TSB or TcB level to assess the newborn's likelihood of developing progressive or severe hyperbilirubinemia and to guide appropriate timing of follow-up. The approach is summarized in the table  (<a class="graphic graphic_table graphicRef139498" href="/d/graphic/139498.html" rel="external">table 2</a>) and discussed separately. (See  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening", section on 'Risk assessment'</a> and  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening", section on 'Outpatient follow-up'</a>.)</p><p></p><p class="bulletIndent1">Other reported risk factors that are not included in the 2022 AAP guidelines include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polycythemia (see  <a class="medical medical_review" href="/d/html/5940.html" rel="external">"Neonatal polycythemia", section on 'Hyperbilirubinemia'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Small-for-gestational-age (SGA) [<a href="#rid11">11</a>] (see  <a class="medical medical_review" href="/d/html/5062.html" rel="external">"Infants with fetal (intrauterine) growth restriction"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Male sex [<a href="#rid12">12</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal age ≥25 years [<a href="#rid13">13</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Newborns cared for at facilities with constrained resources [<a href="#rid21">21</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors associated with lower risk</strong> – Factors reported to be associated with decreased risk of severe hyperbilirubinemia include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gestational age (GA) ≥41 to 42 weeks [<a href="#rid12">12</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Exclusive formula feeding [<a href="#rid12">12,13</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Discharge from the birth hospitalization at &gt;72 hours after birth [<a href="#rid13">13,22</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Planned Cesarean delivery [<a href="#rid11">11</a>]</p><p></p><p class="headingAnchor" id="H2411414803"><span class="h2">Risk factors for neurotoxicity</span><span class="headingEndMark"> — </span>Risk factors for neurotoxicity primarily relate to the amount of unbound bilirubin in the blood and the integrity of the blood brain barrier. The most important risk factor is the severity and duration of bilirubin exposure. Based upon observational studies, the risk of acute and chronic bilirubin encephalopathy (ABE and CBE, respectively) among healthy newborn infants is highest when TSB levels ≥30 mg/dL (513 micromol/L) [<a href="#rid4">4,16,23,24</a>]. Neurotoxicity can occur at lower TSB levels (ie, &gt; 20 to 30 mg/dL (342 to 513 micromol/L) in the setting of Rh disease, severe hemolysis, sepsis, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or other acute illnesses. With progressive hyperbilirubinemia, the margins of safety can be diminished by the rate of TSB rise.</p><p>In addition to the TSB level, the 2022 AAP Clinical Practice Guideline Revision recognizes the following as key risk factors for developing bilirubin neurotoxicity  (<a class="graphic graphic_table graphicRef139425" href="/d/graphic/139425.html" rel="external">table 3</a>) [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>GA &lt;38 weeks (the risk increases with decreasing GA) </p><p class="bulletIndent1"><span class="glyph">●</span>Hemolytic disorders (alloimmune hemolytic disease of the newborn G6PD deficiency, other inherited hemolytic anemias) [<a href="#rid7">7,25</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Clinical or hemodynamic instability </p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial or viral sepsis [<a href="#rid25">25</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoalbuminemia (serum albumin &lt;3.0 g/dL) [<a href="#rid26">26</a>]</p><p></p><p>For some of these factors (eg, hemolysis), the increased risk of developing bilirubin neurotoxicity is a result of the extreme TSB levels associated with the condition, since extreme levels overwhelm the normal bilirubin binding mechanisms. For others (eg, hypoalbuminemia), the increased risk of neurotoxicity is due to reduced bilirubin-albumin binding, which increases the amount of unbound (free) bilirubin  (<a class="graphic graphic_figure graphicRef121543" href="/d/graphic/121543.html" rel="external">figure 2</a>). For some factors (eg, sepsis, hemodynamic instability), both mechanisms are likely at play.</p><p>Other factors that increase vulnerability to bilirubin neurotoxicity either by reducing bilirubin-albumin binding or increasing permeability of the blood-brain barrier include [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Certain drugs (eg, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>, sulfisoxazole, moxalactam) </p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic or respiratory acidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperosmolality</p><p></p><p>Factors contributing to neurotoxicity were illustrated in a study of 125 patients with severe CBE (or kernicterus), all of whom were discharged from the birth hospitalization (presumably healthy at discharge) but then readmitted for management of severe hyperbilirubinemia [<a href="#rid28">28</a>]. The following were identified as contributing causes:</p><p class="bulletIndent1"><span class="glyph">●</span>No clear underlying risk factor – 42 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>G6PD deficiency – 21 percent (when measured).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other hemolytic condition – 20 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bruising from birth trauma – 14 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection – 14 percent (concurrent with other causes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Crigler-Najjar syndrome or galactosemia – 2 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breastfeeding difficulties – Nearly all infants (98 percent) were exclusively breastfed. At the time of readmission, 17 percent had lost &gt;10 percent of their birth weight, suggesting inadequate milk intake. (See  <a class="medical medical_review" href="/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis", section on 'Inadequate milk intake'</a> and  <a class="medical medical_review" href="/d/html/4996.html" rel="external">"Common problems of breastfeeding and weaning", section on 'Inadequate milk intake'</a>.)</p><p></p><p class="headingAnchor" id="H456363"><span class="h2">Risk factors for readmission</span><span class="headingEndMark"> — </span>Risk factors for readmission for hyperbilirubinemia for term infants based on data from a large population-based Australian study included [<a href="#rid29">29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Early birth hospital discharge (≤48 hours after birth).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GA &lt;39 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mother from an Asian country.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal birth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>First-time mother.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breastfeeding at the time of birth hospital discharge. Of note, the study did not differentiate between suboptimal or successful initiation of breastfeeding at the time of discharge.</p><p></p><p class="headingAnchor" id="H3846562772"><span class="h1">GENETIC PREDISPOSITION</span><span class="headingEndMark"> — </span>Genetic predisposition may play a contributing role in the development of severe hyperbilirubinemia. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Gilbert syndrome – Gilbert syndrome affects approximately 5 to 15 percent of the general population and is more common in individuals of East Asian ancestry [<a href="#rid30">30,31</a>]. It is caused by a common mutation in the <em>UGT1A1 </em>gene, which encodes for uridine diphosphate glucuronosyltransferase (UGT). UGT catalyzes the conjugation of bilirubin with glucuronic acid. Thus, affected individuals have decreased bilirubin clearance. The clinical scenario typically presents as persistent jaundice and prolonged unconjugated hyperbilirubinemia at age 10 to 14 days. The relatively high prevalence of this disorder may in part explain why family history is a predictive risk factor for hyperbilirubinemia. In newborns with Gilbert syndrome, reduced bilirubin clearance in combination with any other factor that increases bilirubin (eg, hemolytic disease) can result in severe hyperbilirubinemia [<a href="#rid31">31,32</a>]. As an example, breastfed infants with Gilbert syndrome have an approximately threefold higher risk for developing severe hyperbilirubinemia compared with breastfed infants without Gilbert syndrome [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inherited hemolytic anemias – Newborns with inherited hemolytic disorders (eg, glucose-6-phosphate dehydrogenase [G6PD] deficiency) are at risk of developing severe neonatal hyperbilirubinemia [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children", section on 'Intrinsic hemolytic anemias'</a> and  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Neonatal jaundice'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H8"><span class="h2">Jaundice</span><span class="headingEndMark"> — </span>Jaundice is the yellow color produced by the deposition of bilirubin in the skin and subcutaneous tissues. It can be assessed visually after digital pressure, using color comparison with standardized color charts. Jaundice may also be assessed in the buccal, gingival, or conjunctival mucosa.</p><p>The examination for jaundice should be performed with adequate ambient light or under daylight fluorescent light. Pressing on the skin or oral mucosa with a finger reduces local skin perfusion and facilitates detection of jaundice. </p><p>Jaundice usually progresses in a cephalocaudal direction, appearing first in the face with total serum bilirubin (TSB) levels of 4 to 8 mg/dL (68 to 137 micromol/L). The entire body, including palms and soles, can appear jaundiced at a TSB level &gt;15 mg/dL (257 micromol/L) [<a href="#rid35">35</a>]. However, the extent of visible jaundice on physical examination is <strong>not</strong> a reliable method to estimate TSB levels or identify infants at risk for rapidly rising TSB, especially in those with darkly pigmented skin [<a href="#rid36">36-40</a>]. If there is uncertainty regarding the presence or extent of jaundice, bilirubin should be measured with a TSB level or with a transcutaneous bilirubin (TcB) device. As discussed separately, routine screening with at least one TSB or TcB measurement during the birth hospitalization (typically between 24 to 48 hours after birth) is suggested for all newborn infants ≥35 weeks of gestation. Testing should be performed sooner if the newborn appears jaundiced within the first 24 hours. (See  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a>.) </p><p class="headingAnchor" id="H3470372885"><span class="h2">Scleral or conjunctival icterus</span><span class="headingEndMark"> — </span>Scleral icterus is due to bilirubin deposition in the conjunctiva and subsequently in scleral stroma. It can be observed on scleral examination. The finding of scleral icterus generally correlates with clinically significant hyperbilirubinemia, particularly if observed within the first 48 to 72 hours after birth and subsequently lingers. However, the correlation is not always consistent [<a href="#rid41">41,42</a>]. </p><p>In one study that included 76 infants with scleral icterus, 91 percent had a TSB ≥15 mg/dL (257 micromol/L) [<a href="#rid41">41</a>]. In another study of 689 infants seen in the outpatient setting between 3 and 10 days of age (308 had scleral icterus; 381 did not), the likelihood of having TcB ≥13 mg/dL (222 micromol/L) was far higher among newborns with scleral icterus compared with those without icterus (40 versus 4 percent, respectively) [<a href="#rid42">42</a>]. A limitation of the second study is that it used only TcB measurements, which are less reliable at TSB levels&gt;15 mg/dL (257 micromol/L). (See  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening", section on 'Bilirubin testing methods'</a>.) </p><p class="headingAnchor" id="H1784377038"><span class="h2">Other physical findings</span><span class="headingEndMark"> — </span>Other findings on physical examination may suggest an underlying condition associated with an increased risk for hyperbilirubinemia such as:</p><p class="bulletIndent1"><span class="glyph">●</span>Pallor (in the setting of significant anemia due to hemolysis)</p><p class="bulletIndent1"><span class="glyph">●</span>Enclosed hemorrhage (eg, cephalohematoma)</p><p class="bulletIndent1"><span class="glyph">●</span>Bruising</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatosplenomegaly </p><p></p><p class="headingAnchor" id="H3733261422"><span class="h1">CONSEQUENCES OF SEVERE HYPERBILIRUBINEMIA</span></p><p class="headingAnchor" id="H3115085633"><span class="h2">Bilirubin-induced neurologic disorders (BIND)</span><span class="headingEndMark"> — </span>The major consequence of severe neonatal hyperbilirubinemia is a spectrum of neurotoxic injuries collectively referred to as BIND. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – BIND occurs when free (or unbound) bilirubin crosses the blood-brain barrier and binds to brain tissue. This causes both molecular and cytological injuries to brain cells, which can result in cell death by apoptosis (programmed cell death) and/or necrosis  (<a class="graphic graphic_figure graphicRef121543" href="/d/graphic/121543.html" rel="external">figure 2</a>) [<a href="#rid43">43-45</a>]. The brain regions most often affected include the basal ganglia and the brainstem nuclei for oculomotor and auditory function, accounting for the clinical features seen in infants and children with BIND [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence </strong>– The true incidence of BIND in the general neonatal population is unknown and varies due to multiple epidemiological factors. Among term and late preterm infants with extreme hyperbilirubinemia (total bilirubin [TB] levels ≥30 mg/dL [513 micromol/L]), reported rates of acute and chronic bilirubin encephalopathy (ABE and CBE, respectively) range from 10 to 30 percent [<a href="#rid4">4,16,23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for BIND</strong> – Major risk factors for BIND are summarized in the table  (<a class="graphic graphic_table graphicRef139425" href="/d/graphic/139425.html" rel="external">table 3</a>) and discussed above. (See <a class="local">'Risk factors for neurotoxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical spectrum</strong> – BIND represents a spectrum of neurologic abnormalities, ranging from subtle findings to severe disability [<a href="#rid47">47,48</a>]. </p><p></p><p class="bulletIndent1">Severe CBE (previously referred to as kernicterus), is the extreme form of BIND associated with permanent neurologic sequelae, such as choreoathetoid cerebral palsy, gaze palsies, and sensorineural impairment [<a href="#rid10">10</a>]. (See <a class="local">'Incidence'</a> below.)</p><p></p><p class="bulletIndent1">Less severe manifestations of BIND can be observed in vulnerable neonates exposed to bilirubin of a lesser degree than typically associated with CBE (generally TSB &lt;25 mg/dL [428 micromol/L]). These subtle clinical neuromotor manifestations may include [<a href="#rid47">47</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disorders in visuocortical pathways [<a href="#rid49">49</a>] </p><p class="bulletIndent2"><span class="glyph">•</span>Sensorineural hearing loss [<a href="#rid50">50</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal proprioception (leading to gait abnormalities) [<a href="#rid51">51</a>] </p><p class="bulletIndent2"><span class="glyph">•</span>Speech and language disabilities [<a href="#rid52">52</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Processing disorders</p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive delays [<a href="#rid52">52</a>]</p><p></p><p class="bulletIndent1">However, the literature linking subtle neurologic abnormalities with hyperbilirubinemia is conflicting [<a href="#rid10">10,53-56</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Acute bilirubin encephalopathy (ABE)</span><span class="headingEndMark"> — </span>ABE refers to acute signs of bilirubin neurotoxicity in a newborn with severe persistent hyperbilirubinemia. </p><p class="headingAnchor" id="H1222099827"><span class="h3">Incidence</span><span class="headingEndMark"> — </span>Based on information from population-based studies in resource-abundant settings, the estimated incidence of ABE is approximately 0.5 to 1 per 100,000 live-born infants [<a href="#rid4">4,6,7,16</a>]. Among newborn infants with total serum or plasma (TSB) &gt;30 mg/dL (513 micromol/L), reported rates of ABE range from 2 to 10 percent. </p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of infants from a single healthcare system in the United States born between 1995 and 2011, 47 of 525,409 infants (0.01 percent) had at least one TSB level &gt;30 mg/dL (513 micromol/L). Four of these 47 patients (9 percent) had clinical signs of ABE and all had TSB &gt;35 mg/dL (599 micromol/L) [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a Danish population study, five of 224 infants (2 percent) with TSB ≥30 mg/dL (513 micromol/L) developed ABE; three with severe ABE had peak TSB levels of 38 to 57.7 mg/dL (650 to 9987 micromol/L) that resulted in kernicterus or CBE [<a href="#rid16">16</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another population-based study from the United Kingdom and Ireland, 14 of 108 infants (13 percent) with TSB &gt;30 mg/dL (513 micromol/L) showed evidence of ABE including three who died [<a href="#rid6">6</a>].</p><p></p><p>The risk may be higher with resource-constrained healthcare systems. In an observational case series from Egypt of 249 infants with TSB &gt;25 mg/dL (428 micromol/L) for unknown duration, moderate or severe ABE was diagnosed in 44 infants (18 percent) and mild ABE in 55 infants (22 percent) based on neurologic assessment using an objective BIND protocol (BIND score, which is discussed below) [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H1409805236"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>ABE typically progresses through three phases [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early</strong> – In the early phase, the clinical signs may be subtle. The infant is sleepy but arousable, and when aroused has mild to moderate hypotonia and a high-pitched cry. It is challenging to diagnosis ABE during this phase [<a href="#rid23">23</a>]. Early ABE may be reversible. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate</strong> – If there is no intervention, the intermediate phase evolves with progression and persistence of hyperbilirubinemia. The infant can be febrile and lethargic with a poor suck or irritable and jittery with a strong suck. The cry can be shrill and the infant can be difficult to console. Mild to moderate hypertonia develops, beginning with backward arching of the neck (retrocollis) and trunk (opisthotonos) with stimulation. An emergent exchange transfusion at this stage might prevent permanent BIND.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced</strong> – The advanced phase is characterized by apnea, inability to feed, fever, seizures, and a semicomatose state that progresses to coma. Hypertonicity presents as persistent retrocollis and opisthotonos with bicycling or twitching of the hands and feet. The cry is inconsolable or may be weak or absent. Death can occur, primarily due to respiratory failure or intractable seizures.</p><p></p><p>Early ABE may be reversible, but if the high TSB level is not addressed promptly, it may result in permanent irreversible neurologic sequelae (CBE). (See <a class="local">'Chronic bilirubin encephalopathy (kernicterus)'</a> below.)</p><p>Clinical signs associated with ABE can be divided into three domains  (<a class="graphic graphic_table graphicRef122620" href="/d/graphic/122620.html" rel="external">table 4</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Mental status</p><p class="bulletIndent1"><span class="glyph">●</span>Tone</p><p class="bulletIndent1"><span class="glyph">●</span>Cry pattern </p><p></p><p>In neonates with severe hyperbilirubinemia and without any other identifiable cause of neurologic impairment, the severity of each domain is used to determine the overall severity of ABE using the BIND score  (<a class="graphic graphic_table graphicRef122620" href="/d/graphic/122620.html" rel="external">table 4</a>). </p><p>Brainstem auditory-evoked responses (BAER) can also be used to detect the acute neurologic effects of hyperbilirubinemia and confirm the presence of BIND [<a href="#rid58">58-61</a>]. In one study, elevated TSB levels correlated with prolonged brainstem conduction time [<a href="#rid59">59</a>]. These abnormalities resolve as TSB values decline. </p><p class="headingAnchor" id="H11"><span class="h2">Chronic bilirubin encephalopathy (kernicterus)</span><span class="headingEndMark"> — </span>CBE (previously referred to as kernicterus) is a permanent post-icteric brain injury characterized by choreoathetoid cerebral palsy and other chronic neurologic impairments.</p><p class="headingAnchor" id="H4258372026"><span class="h3">Incidence</span><span class="headingEndMark"> — </span>Reported incidence rates of CBE in resource-abundant countries (eg, Canada, Denmark, Sweden, and the United States) range from 0.4 to 2.3 per 100,000 live births per year [<a href="#rid5">5,25,34,62,63</a>]. </p><p>Among newborns with hyperbilirubinemia, the risk of developing CBE depends upon the severity and duration of hyperbilirubinemia. Based upon population data from resource-abundant countries, the estimated risk according to predischarge TSB levels is as follows [<a href="#rid21">21,62,64</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>TSB &gt;20 and ≤25 mg/dL (342 and 428 micromol/L) – CBE is extremely rare</p><p class="bulletIndent1"><span class="glyph">●</span>TSB &gt;25 and ≤30 mg/dL (428 and 513 micromol/L) – Approximately 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>TSB &gt;30 and ≤35 mg/dL (513 and 599 micromol/L) – Approximately 10 to 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>TSB &gt;35 mg/dL (599 micromol/L) – Almost all infants will develop signs of CBE</p><p></p><p>Two advances in medical care have impacted how hyperbilirubinemia is managed and have altered the associated morbidity and mortality. They include the widespread use of Rh(D) immunoglobulin to Rh-negative mothers, which dramatically decreased the incidence of Rh-isoimmune neonatal hemolytic disease, and the introduction of phototherapy, which significantly reduced the need for exchange transfusions and the risk of developing severe hyperbilirubinemia. (See  <a class="medical medical_review" href="/d/html/6773.html" rel="external">"RhD alloimmunization: Prevention in pregnant and postpartum patients"</a> and  <a class="medical medical_review" href="/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Initial intervention (phototherapy)'</a>.) </p><p>Thus, an infant's risk of developing CBE has declined considerably from its peak in the 1950s through the 1970s. Nevertheless, isolated cases of CBE, a mostly preventable condition, continue to be reported despite the implementation of practice guidelines [<a href="#rid9">9,65-68</a>]. In particular, infants with hemolytic diseases (eg, glucose-6-phosphate dehydrogenase [G6PD] deficiency) are at risk for developing severe hyperbilirubinemia and CBE [<a href="#rid10">10,68-70</a>]. </p><p>Reported cases of CBE have declined in many parts of the world after the adoption of universal newborn bilirubin screening. However, there still is a significant risk for death in infants with CBE [<a href="#rid28">28,71</a>]. In the United States, 31 deaths associated with CBE were reported during the period between 1979 and 2006 (0.28 deaths per million live births) [<a href="#rid71">71</a>]. </p><p class="headingAnchor" id="H2702813588"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>CBE usually develops during the first year after birth [<a href="#rid46">46,72</a>]. </p><p>The characteristic findings of CBE include:</p><p class="bulletIndent1"><span class="glyph">●</span>Choreoathetoid cerebral palsy (chorea, ballismus, tremor, and dystonia). (See  <a class="medical medical_review" href="/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sensorineural hearing loss due to auditory neuropathy (abnormal BAER with normal OAE) [<a href="#rid73">73,74</a>]. (See  <a class="medical medical_review" href="/d/html/6308.html" rel="external">"Hearing loss in children: Etiology", section on 'Hyperbilirubinemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gaze palsies, especially limitation of upward gaze.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dental enamel hypoplasia.</p><p></p><p>In general, cognitive function is relatively spared. The major neurologic features of CBE reflect the classic affected areas of the brain (basal ganglia and the brainstem nuclei for oculomotor and auditory functions). Abnormal findings on magnetic resonance imaging typically involve the cerebellum, hippocampus, and brainstem [<a href="#rid75">75,76</a>]. </p><p>Most infants who develop CBE will have manifested signs of ABE during the neonatal period [<a href="#rid36">36</a>]. However, there are reported cases of infants who developed CBE with few or no signs of ABE [<a href="#rid77">77,78</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Hyperbilirubinemia and autism</span><span class="headingEndMark"> — </span>Whether hyperbilirubinemia is associated with increased risk of autism spectrum disorders (ASD) remains uncertain. The available reports have reached variable conclusions: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies reporting no association</strong> – In a retrospective nested case-control study from a single healthcare system that included 2155 children (338 with ASD and 1817 matched controls without ASD), the proportion of children who had been exposed to TSB &gt;20 mg/dL (342 micromol/L) was similar in both groups (2.1 percent versus 2.5 percent) [<a href="#rid79">79</a>]. After adjusting for other factors (gestational age, sex, birth facility, maternal age, maternal race/ethnicity, maternal education), neonatal hyperbilirubinemia did not appear to be a significant predictor of ASD later in childhood. Exposure to phototherapy was also not associated with risk of ASD. </p><p></p><p class="bulletIndent1">Similarly, an earlier case-control study from the same healthcare system also did not find an association between ASD and neonatal exposure to various degrees of hyperbilirubinemia (TSB 15 to &lt;20 mg/dL [257 to 342 micromol/L], TSB 20 to &lt;25 mg/dL [342 to 428 micromol/L], or TSB ≥25 mg/dL [≥428 micromol/L]) [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies reporting a possible association</strong> – In a population-based study from Denmark using data collected from four national registries including 733,826 infants born between 1994 and 2004, neonatal hyperbilirubinemia was associated with an increased risk of neurobehavioral disorders, including ASD (hazard ratio [HR] 1.67, 95% CI 1.03-2.71) [<a href="#rid81">81</a>]. </p><p></p><p class="bulletIndent1">Another population-based study from Nova Scotia that included 61,238 infants born between 1994 and 2000 reported an association between neonatal exposure to TSB &gt;19 mg/dL (325 micromol/L) and later development of ADHD, developmental delay, and ASD [<a href="#rid55">55</a>]. However, the association between hyperbilirubinemia and ASD was of borderline statistical significance (adjusted risk ratio [aRR] 1.6, 95% CI 1.0-2.5).</p><p></p><p class="headingAnchor" id="H4094479556"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116513.html" rel="external">"Society guideline links: Neonatal jaundice"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15455.html" rel="external">"Patient education: Jaundice in babies (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1203.html" rel="external">"Patient education: Jaundice in newborn infants (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> – Elevated total serum bilirubin (TSB) levels occur in nearly all newborn infants and may present with visible jaundice. Infants with severe hyperbilirubinemia (TSB &gt;25 mg/dL [428 micromol/L]) are at risk for developing bilirubin neurotoxicity. If hyperbilirubinemia in this range is not treated promptly, it can result in severe permanent neurologic injury. (See <a class="local">'Introduction'</a> above and <a class="local">'Consequences of severe hyperbilirubinemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The estimated incidence of severe hyperbilirubinemia (defined as TSB &gt;25 mg/dL [428 micromol/L]) varies globally, ranging from approximately 10 to 40 per 100,000 live births. The variation may be due to differences in breastfeeding practices and genetic factors that affect bilirubin production and metabolism. (See <a class="local">'Incidence of neonatal hyperbilirubinemia'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For severe hyperbilirubinemia </strong>– The strongest predictor for developing severe hyperbilirubinemia is the newborn’s predischarge TSB or transcutaneous bilirubin (TcB) level, which is typically measured at 24 to 48 hours after birth. The newborn hyperbilirubinemia assessment calculator (<a class="calc calc_professional" href="/d/html/13421.html" rel="external">calculator 1</a>) can be used to assess the risk of developing severe hyperbilirubinemia and determine the hour-specific TSB threshold for treatment. Additional factors associated with increased risk of progressive or severe hyperbilirubinemia are summarized in the table  (<a class="graphic graphic_table graphicRef64584" href="/d/graphic/64584.html" rel="external">table 1</a>). (See <a class="local">'Risk factors for severe hyperbilirubinemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For neurotoxicity</strong> – The most important risk factor for neurotoxicity is the severity and duration of bilirubin exposure. The risk is highest with TSB ≥30 mg/dL (513 micromol/L). Additional factors associated with increased risk of bilirubin neurotoxicity are summarized in the table  (<a class="graphic graphic_table graphicRef139425" href="/d/graphic/139425.html" rel="external">table 3</a>). (See <a class="local">'Risk factors for neurotoxicity'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The main clinical features of neonatal hyperbilirubinemia are jaundice and scleral icterus. (See <a class="local">'Jaundice'</a> above and <a class="local">'Scleral or conjunctival icterus'</a> above.)</p><p></p><p class="bulletIndent1">However, the extent of visible jaundice is <strong>not</strong> a reliable method to estimate TSB levels or identify newborns at risk for rapidly rising bilirubin, especially in those with darkly pigmented skin. If there is uncertainty regarding the presence or extent of jaundice, TSB or TcB should be measured. As discussed separately, at least one screening TSB or TcB measurement is suggested for all newborns during the birth hospitalization, typically between 24 to 48 hours after birth, or sooner if the newborn appears jaundiced. (See  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic consequences of severe hyperbilirubinemia</strong> – The major consequence of severe neonatal hyperbilirubinemia is a spectrum of neurotoxic injuries collectively referred to as bilirubin-induced neurologic disorders (BIND). The clinical spectrum of BIND ranges from subtle findings to severe permanent disability. (See <a class="local">'Bilirubin-induced neurologic disorders (BIND)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute bilirubin encephalopathy (ABE)</strong> – ABE refers to acute signs of neurotoxicity. Clinical findings may be subtle initially (sleepiness, mild hypotonia, high-pitched cry). Without intervention, ABE can progress to more severe manifestations (apnea, seizures, severe hypertonia) and ultimately coma or death  (<a class="graphic graphic_table graphicRef122620" href="/d/graphic/122620.html" rel="external">table 4</a>). (See <a class="local">'Acute bilirubin encephalopathy (ABE)'</a> above.)</p><p></p><p class="bulletIndent2">The incidence of ABE is approximately 1 per 100,000 live births. Among newborns with extreme hyperbilirubinemia (TSB ≥30 mg/dL [513 micromol/L]), reported rates of ABE range from 2 to 10 percent. (See <a class="local">'Incidence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic bilirubin encephalopathy (CBE)</strong> – CBE (formerly called kernicterus) is a permanent post-icteric brain injury characterized by choreoathetoid cerebral palsy, sensorineural hearing loss, gaze palsies, and other chronic neurologic impairments. (See <a class="local">'Chronic bilirubin encephalopathy (kernicterus)'</a> above.)</p><p></p><p class="bulletIndent2">CBE is rare, with reported incidence rates ranging from 0.4 to 2.3 per 100,000 live births. (See <a class="local">'Incidence'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Newman TB, Liljestrand P, Escobar GJ. Infants with bilirubin levels of 30 mg/dL or more in a large managed care organization. Pediatrics 2003; 111:1303.</a></li><li><a class="nounderline abstract_t">Newman TB, Liljestrand P, Escobar GJ. Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med 2005; 159:113.</a></li><li><a class="nounderline abstract_t">Wickremasinghe AC, Kuzniewicz MW, Newman TB. Black race is not protective against hazardous bilirubin levels. J Pediatr 2013; 162:1068.</a></li><li><a class="nounderline abstract_t">Kuzniewicz MW, Wickremasinghe AC, Wu YW, et al. Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. Pediatrics 2014; 134:504.</a></li><li><a class="nounderline abstract_t">Donneborg ML, Hansen BM, Vandborg PK, et al. Extreme neonatal hyperbilirubinemia and kernicterus spectrum disorder in Denmark during the years 2000-2015. J Perinatol 2020; 40:194.</a></li><li><a class="nounderline abstract_t">Manning D, Todd P, Maxwell M, Jane Platt M. Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed 2007; 92:F342.</a></li><li><a class="nounderline abstract_t">McGillivray A, Polverino J, Badawi N, Evans N. Prospective Surveillance of Extreme Neonatal Hyperbilirubinemia in Australia. J Pediatr 2016; 168:82.</a></li><li><a class="nounderline abstract_t">Sgro M, Kandasamy S, Shah V, et al. Severe Neonatal Hyperbilirubinemia Decreased after the 2007 Canadian Guidelines. J Pediatr 2016; 171:43.</a></li><li><a class="nounderline abstract_t">Christensen RD, Lambert DK, Henry E, et al. Unexplained extreme hyperbilirubinemia among neonates in a multihospital healthcare system. Blood Cells Mol Dis 2013; 50:105.</a></li><li><a class="nounderline abstract_t">Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Norman M, Åberg K, Holmsten K, et al. Predicting Nonhemolytic Neonatal Hyperbilirubinemia. Pediatrics 2015; 136:1087.</a></li><li><a class="nounderline abstract_t">Newman TB, Xiong B, Gonzales VM, Escobar GJ. Prediction and prevention of extreme neonatal hyperbilirubinemia in a mature health maintenance organization. Arch Pediatr Adolesc Med 2000; 154:1140.</a></li><li><a class="nounderline abstract_t">Maisels MJ, Kring E. Length of stay, jaundice, and hospital readmission. Pediatrics 1998; 101:995.</a></li><li><a class="nounderline abstract_t">Keren R, Luan X, Friedman S, et al. A comparison of alternative risk-assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants. Pediatrics 2008; 121:e170.</a></li><li><a class="nounderline abstract_t">Newman TB, Liljestrand P, Escobar GJ. Jaundice noted in the first 24 hours after birth in a managed care organization. Arch Pediatr Adolesc Med 2002; 156:1244.</a></li><li><a class="nounderline abstract_t">Ebbesen F, Bjerre JV, Vandborg PK. Relation between serum bilirubin levels ≥450 μmol/L and bilirubin encephalopathy; a Danish population-based study. Acta Paediatr 2012; 101:384.</a></li><li><a class="nounderline abstract_t">Gale R, Seidman DS, Dollberg S, Stevenson DK. Epidemiology of neonatal jaundice in the Jerusalem population. J Pediatr Gastroenterol Nutr 1990; 10:82.</a></li><li><a class="nounderline abstract_t">Berk MA, Mimouni F, Miodovnik M, et al. Macrosomia in infants of insulin-dependent diabetic mothers. Pediatrics 1989; 83:1029.</a></li><li><a class="nounderline abstract_t">Peevy KJ, Landaw SA, Gross SJ. Hyperbilirubinemia in infants of diabetic mothers. Pediatrics 1980; 66:417.</a></li><li><a class="nounderline abstract_t">Flaherman VJ, Schaefer EW, Kuzniewicz MW, et al. Early weight loss nomograms for exclusively breastfed newborns. Pediatrics 2015; 135:e16.</a></li><li><a class="nounderline abstract_t">Bhutani VK, Zipursky A, Blencowe H, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res 2013; 74 Suppl 1:86.</a></li><li><a class="nounderline abstract_t">Soskolne EI, Schumacher R, Fyock C, et al. The effect of early discharge and other factors on readmission rates of newborns. Arch Pediatr Adolesc Med 1996; 150:373.</a></li><li><a class="nounderline abstract_t">Sgro M, Campbell D, Barozzino T, Shah V. Acute neurological findings in a national cohort of neonates with severe neonatal hyperbilirubinemia. J Perinatol 2011; 31:392.</a></li><li><a class="nounderline abstract_t">Gotink MJ, Benders MJ, Lavrijsen SW, et al. Severe neonatal hyperbilirubinemia in the Netherlands. Neonatology 2013; 104:137.</a></li><li><a class="nounderline abstract_t">Sgro M, Campbell DM, Kandasamy S, Shah V. Incidence of chronic bilirubin encephalopathy in Canada, 2007-2008. Pediatrics 2012; 130:e886.</a></li><li><a class="nounderline abstract_t">Iskander I, Gamaleldin R, El Houchi S, et al. Serum bilirubin and bilirubin/albumin ratio as predictors of bilirubin encephalopathy. Pediatrics 2014; 134:e1330.</a></li><li><a class="nounderline abstract_t">Bratlid D. How bilirubin gets into the brain. Clin Perinatol 1990; 17:449.</a></li><li><a class="nounderline abstract_t">Johnson L, Bhutani VK, Karp K, et al. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol 2009; 29 Suppl 1:S25.</a></li><li><a class="nounderline abstract_t">Lain SJ, Roberts CL, Bowen JR, Nassar N. Early discharge of infants and risk of readmission for jaundice. Pediatrics 2015; 135:314.</a></li><li><a class="nounderline abstract_t">Kadakol A, Sappal BS, Ghosh SS, et al. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. J Med Genet 2001; 38:244.</a></li><li><a class="nounderline abstract_t">Kaplan M, Renbaum P, Levy-Lahad E, et al. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci U S A 1997; 94:12128.</a></li><li><a class="nounderline abstract_t">Watchko JF. Vigintiphobia revisited. Pediatrics 2005; 115:1747.</a></li><li><a class="nounderline abstract_t">Huang MJ, Kua KE, Teng HC, et al. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 2004; 56:682.</a></li><li><a class="nounderline abstract_t">Wu YW, Kuzniewicz MW, Wickremasinghe AC, et al. Risk for cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study. JAMA Pediatr 2015; 169:239.</a></li><li><a class="nounderline abstract_t">Knudsen A, Ebbesen F. Cephalocaudal progression of jaundice in newborns admitted to neonatal intensive care units. Biol Neonate 1997; 71:357.</a></li><li><a class="nounderline abstract_t">Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr 2002; 140:396.</a></li><li><a class="nounderline abstract_t">Moyer VA, Ahn C, Sneed S. Accuracy of clinical judgment in neonatal jaundice. Arch Pediatr Adolesc Med 2000; 154:391.</a></li><li><a class="nounderline abstract_t">Tayaba R, Gribetz D, Gribetz I, Holzman IR. Noninvasive estimation of serum bilirubin. Pediatrics 1998; 102:E28.</a></li><li><a class="nounderline abstract_t">Riskin A, Tamir A, Kugelman A, et al. Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia? J Pediatr 2008; 152:782.</a></li><li><a class="nounderline abstract_t">Keren R, Tremont K, Luan X, Cnaan A. Visual assessment of jaundice in term and late preterm infants. Arch Dis Child Fetal Neonatal Ed 2009; 94:F317.</a></li><li><a class="nounderline abstract_t">Azzuqa A, Watchko JF. Bilirubin Concentrations in Jaundiced Neonates with Conjunctival Icterus. J Pediatr 2015; 167:840.</a></li><li><a class="nounderline abstract_t">Maisels MJ, Coffey MP, Gendelman B, et al. Diagnosing Jaundice by Eye-Outpatient Assessment of Conjunctival Icterus in the Newborn. J Pediatr 2016; 172:212.</a></li><li><a class="nounderline abstract_t">Hankø E, Hansen TW, Almaas R, et al. Bilirubin induces apoptosis and necrosis in human NT2-N neurons. Pediatr Res 2005; 57:179.</a></li><li><a class="nounderline abstract_t">Grojean S, Koziel V, Vert P, Daval JL. Bilirubin induces apoptosis via activation of NMDA receptors in developing rat brain neurons. Exp Neurol 2000; 166:334.</a></li><li><a class="nounderline abstract_t">Rodrigues CM, Solá S, Brites D. Bilirubin induces apoptosis via the mitochondrial pathway in developing rat brain neurons. Hepatology 2002; 35:1186.</a></li><li class="breakAll">Volpe JJ. Neurology of the Newborn, 4th ed, WB Saunders, Philadelphia 2001.</li><li><a class="nounderline abstract_t">Bhutani VK, Wong R. Bilirubin-induced neurologic dysfunction (BIND). Semin Fetal Neonatal Med 2015; 20:1.</a></li><li><a class="nounderline abstract_t">Johnson L, Bhutani VK. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Perinatol 2011; 35:101.</a></li><li><a class="nounderline abstract_t">Good WV, Hou C. Visuocortical bilirubin-induced neurological dysfunction. Semin Fetal Neonatal Med 2015; 20:37.</a></li><li><a class="nounderline abstract_t">Olds C, Oghalai JS. Audiologic impairment associated with bilirubin-induced neurologic damage. Semin Fetal Neonatal Med 2015; 20:42.</a></li><li><a class="nounderline abstract_t">Rose J, Vassar R. Movement disorders due to bilirubin toxicity. Semin Fetal Neonatal Med 2015; 20:20.</a></li><li><a class="nounderline abstract_t">Wusthoff CJ, Loe IM. Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes. Semin Fetal Neonatal Med 2015; 20:52.</a></li><li><a class="nounderline abstract_t">Vandborg PK, Hansen BM, Greisen G, et al. Follow-up of extreme neonatal hyperbilirubinaemia in 5- to 10-year-old children: a Danish population-based study. Dev Med Child Neurol 2015; 57:378.</a></li><li><a class="nounderline abstract_t">Newman TB, Liljestrand P, Jeremy RJ, et al. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med 2006; 354:1889.</a></li><li><a class="nounderline abstract_t">Jangaard KA, Fell DB, Dodds L, Allen AC. Outcomes in a population of healthy term and near-term infants with serum bilirubin levels of &gt;or=325 micromol/L (&gt;or=19 mg/dL) who were born in Nova Scotia, Canada, between 1994 and 2000. Pediatrics 2008; 122:119.</a></li><li><a class="nounderline abstract_t">Lunsing RJ, Pardoen WF, Hadders-Algra M. Neurodevelopment after moderate hyperbilirubinemia at term. Pediatr Res 2013; 73:655.</a></li><li><a class="nounderline abstract_t">Gamaleldin R, Iskander I, Seoud I, et al. Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. Pediatrics 2011; 128:e925.</a></li><li><a class="nounderline abstract_t">Vohr BR, Karp D, O'Dea C, et al. Behavioral changes correlated with brain-stem auditory evoked responses in term infants with moderate hyperbilirubinemia. J Pediatr 1990; 117:288.</a></li><li><a class="nounderline abstract_t">Gupta AK, Mann SB. Is auditory brainstem response a bilirubin neurotoxicity marker? Am J Otolaryngol 1998; 19:232.</a></li><li><a class="nounderline abstract_t">Agrawal VK, Shukla R, Misra PK, et al. Brainstem auditory evoked response in newborns with hyperbilirubinemia. Indian Pediatr 1998; 35:513.</a></li><li><a class="nounderline abstract_t">Ahlfors CE, Parker AE. Unbound bilirubin concentration is associated with abnormal automated auditory brainstem response for jaundiced newborns. Pediatrics 2008; 121:976.</a></li><li><a class="nounderline abstract_t">Alkén J, Håkansson S, Ekéus C, et al. Rates of Extreme Neonatal Hyperbilirubinemia and Kernicterus in Children and Adherence to National Guidelines for Screening, Diagnosis, and Treatment in Sweden. JAMA Netw Open 2019; 2:e190858.</a></li><li><a class="nounderline abstract_t">Burke BL, Robbins JM, Bird TM, et al. Trends in hospitalizations for neonatal jaundice and kernicterus in the United States, 1988-2005. Pediatrics 2009; 123:524.</a></li><li><a class="nounderline abstract_t">Bhutani VK, Johnson L. Kernicterus in the 21st century: frequently asked questions. J Perinatol 2009; 29 Suppl 1:S20.</a></li><li><a class="nounderline abstract_t">Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103:6.</a></li><li><a class="nounderline abstract_t">Maisels MJ, Newman TB. Kernicterus in otherwise healthy, breast-fed term newborns. Pediatrics 1995; 96:730.</a></li><li><a class="nounderline abstract_t">Mah JK, Wirrell E. All is not well: the continual challenges of bilirubin encephalopathy. Can J Neurol Sci 2005; 32:273.</a></li><li><a class="nounderline abstract_t">Bhutani VK, Johnson LH, Jeffrey Maisels M, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol 2004; 24:650.</a></li><li><a class="nounderline abstract_t">Watchko JF, Kaplan M, Stark AR, et al. Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States? J Perinatol 2013; 33:499.</a></li><li><a class="nounderline abstract_t">Nock ML, Johnson EM, Krugman RR, et al. Implementation and analysis of a pilot in-hospital newborn screening program for glucose-6-phosphate dehydrogenase deficiency in the United States. J Perinatol 2011; 31:112.</a></li><li><a class="nounderline abstract_t">Brooks JC, Fisher-Owens SA, Wu YW, et al. Evidence suggests there was not a "resurgence" of kernicterus in the 1990s. Pediatrics 2011; 127:672.</a></li><li><a class="nounderline abstract_t">van Toorn R, Brink P, Smith J, et al. Bilirubin-Induced Neurological Dysfunction: A Clinico-Radiological-Neurophysiological Correlation in 30 Consecutive Children. J Child Neurol 2016; 31:1579.</a></li><li><a class="nounderline abstract_t">Wickremasinghe AC, Risley RJ, Kuzniewicz MW, et al. Risk of Sensorineural Hearing Loss and Bilirubin Exchange Transfusion Thresholds. Pediatrics 2015; 136:505.</a></li><li><a class="nounderline abstract_t">Amin SB, Saluja S, Saili A, et al. Chronic Auditory Toxicity in Late Preterm and Term Infants With Significant Hyperbilirubinemia. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Wisnowski JL, Panigrahy A, Painter MJ, Watchko JF. Magnetic Resonance Imaging Abnormalities in Advanced Acute Bilirubin Encephalopathy Highlight Dentato-Thalamo-Cortical Pathways. J Pediatr 2016; 174:260.</a></li><li><a class="nounderline abstract_t">Wisnowski JL, Panigrahy A, Painter MJ, Watchko JF. Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise. Semin Perinatol 2014; 38:422.</a></li><li><a class="nounderline abstract_t">VAN PRAAGH R. Diagnosis of kernicterus in the neonatal period. Pediatrics 1961; 28:870.</a></li><li><a class="nounderline abstract_t">JONES MH, SANDS R, HYMAN CB, et al. Longitudinal study of the incidence of central nervous system damage following erythroblastosis fetalis. Pediatrics 1954; 14:346.</a></li><li><a class="nounderline abstract_t">Wu YW, Kuzniewicz MW, Croen L, et al. Risk of Autism Associated With Hyperbilirubinemia and Phototherapy. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Croen LA, Yoshida CK, Odouli R, Newman TB. Neonatal hyperbilirubinemia and risk of autism spectrum disorders. Pediatrics 2005; 115:e135.</a></li><li><a class="nounderline abstract_t">Maimburg RD, Bech BH, Vaeth M, et al. Neonatal jaundice, autism, and other disorders of psychological development. Pediatrics 2010; 126:872.</a></li></ol></div><div id="topicVersionRevision">Topic 4994 Version 69.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12777545" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Infants with bilirubin levels of 30 mg/dL or more in a large managed care organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699303" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23403251" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Black race is not protective against hazardous bilirubin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25092943" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31907395" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Extreme neonatal hyperbilirubinemia and kernicterus spectrum disorder in Denmark during the years 2000-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074786" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the UK and Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26477873" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prospective Surveillance of Extreme Neonatal Hyperbilirubinemia in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26852177" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe Neonatal Hyperbilirubinemia Decreased after the 2007 Canadian Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23123126" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Unexplained extreme hyperbilirubinemia among neonates in a multihospital healthcare system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35927462" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26553185" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predicting Nonhemolytic Neonatal Hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074857" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prediction and prevention of extreme neonatal hyperbilirubinemia in a mature health maintenance organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9606225" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Length of stay, jaundice, and hospital readmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166536" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A comparison of alternative risk-assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12444838" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Jaundice noted in the first 24 hours after birth in a managed care organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22176133" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Relation between serum bilirubin levels≥450μmol/L and bilirubin encephalopathy; a Danish population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2324884" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epidemiology of neonatal jaundice in the Jerusalem population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2726329" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Macrosomia in infants of insulin-dependent diabetic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7422431" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hyperbilirubinemia in infants of diabetic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25554815" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Early weight loss nomograms for exclusively breastfed newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366465" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634731" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The effect of early discharge and other factors on readmission rates of newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21151009" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Acute neurological findings in a national cohort of neonates with severe neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23887661" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Severe neonatal hyperbilirubinemia in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22966025" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence of chronic bilirubin encephalopathy in Canada, 2007-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25332491" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Serum bilirubin and bilirubin/albumin ratio as predictors of bilirubin encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2196140" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : How bilirubin gets into the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19177057" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical report from the pilot USA Kernicterus Registry (1992 to 2004).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25583922" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Early discharge of infants and risk of readmission for jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11370628" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9342374" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930239" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vigintiphobia revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319464" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk factors for severe hyperbilirubinemia in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25560920" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk for cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9197337" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cephalocaudal progression of jaundice in newborns admitted to neonatal intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12006952" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : System-based approach to management of neonatal jaundice and prevention of kernicterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768679" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Accuracy of clinical judgment in neonatal jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9724676" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Noninvasive estimation of serum bilirubin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18492516" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307221" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Visual assessment of jaundice in term and late preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26239927" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bilirubin Concentrations in Jaundiced Neonates with Conjunctival Icterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26898809" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Diagnosing Jaundice by Eye-Outpatient Assessment of Conjunctival Icterus in the Newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15611354" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bilirubin induces apoptosis and necrosis in human NT2-N neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11085898" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bilirubin induces apoptosis via activation of NMDA receptors in developing rat brain neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981769" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bilirubin induces apoptosis via the mitochondrial pathway in developing rat brain neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981769" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bilirubin induces apoptosis via the mitochondrial pathway in developing rat brain neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577656" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bilirubin-induced neurologic dysfunction (BIND).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21641482" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The clinical syndrome of bilirubin-induced neurologic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577655" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Visuocortical bilirubin-induced neurological dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575899" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Audiologic impairment associated with bilirubin-induced neurologic damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25524299" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Movement disorders due to bilirubin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25585889" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25353277" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Follow-up of extreme neonatal hyperbilirubinaemia in 5- to 10-year-old children: a Danish population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672700" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18595994" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcomes in a population of healthy term and near-term infants with serum bilirubin levels of&gt;or=325 micromol/L (&gt;or=19 mg/dL) who were born in Nova Scotia, Canada, between 1994 and 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23407118" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Neurodevelopment after moderate hyperbilirubinemia at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911352" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2380830" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Behavioral changes correlated with brain-stem auditory evoked responses in term infants with moderate hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692630" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Is auditory brainstem response a bilirubin neurotoxicity marker?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216645" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Brainstem auditory evoked response in newborns with hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450902" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Unbound bilirubin concentration is associated with abnormal automated auditory brainstem response for jaundiced newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30901042" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Rates of Extreme Neonatal Hyperbilirubinemia and Kernicterus in Children and Adherence to National Guidelines for Screening, Diagnosis, and Treatment in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171618" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Trends in hospitalizations for neonatal jaundice and kernicterus in the United States, 1988-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19177056" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Kernicterus in the 21st century: frequently asked questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9917432" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7567339" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Kernicterus in otherwise healthy, breast-fed term newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16225165" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : All is not well: the continual challenges of bilirubin encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15254556" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Kernicterus: epidemiological strategies for its prevention through systems-based approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429543" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20539275" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Implementation and analysis of a pilot in-hospital newborn screening program for glucose-6-phosphate dehydrogenase deficiency in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444599" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evidence suggests there was not a "resurgence" of kernicterus in the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27591005" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bilirubin-Induced Neurological Dysfunction: A Clinico-Radiological-Neurophysiological Correlation in 30 Consecutive Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283777" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Risk of Sensorineural Hearing Loss and Bilirubin Exchange Transfusion Thresholds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28954873" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Chronic Auditory Toxicity in Late Preterm and Term Infants With Significant Hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113379" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Magnetic Resonance Imaging Abnormalities in Advanced Acute Bilirubin Encephalopathy Highlight Dentato-Thalamo-Cortical Pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267277" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13924616" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Diagnosis of kernicterus in the neonatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13204103" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Longitudinal study of the incidence of central nervous system damage following erythroblastosis fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27669736" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk of Autism Associated With Hyperbilirubinemia and Phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15687420" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Neonatal hyperbilirubinemia and risk of autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937652" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Neonatal jaundice, autism, and other disorders of psychological development.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
